Is EVMN or FBRX more undervalued in 2026?

CirclFi compares Evommune, Inc. (EVMN) and Forte Biosciences, Inc. (FBRX) using 13 institutional-grade valuation models. EVMN has a Quality of Company score of 6.0/10 while FBRX scores 4.1/10.

Which is a better buy — EVMN or FBRX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EVMN and FBRX valuations compare?

EVMN at $23.23 and FBRX at $19.07 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EVMN vs FBRX Valuation Comparison 2026 — Intrinsic Value Analysis

EVMN

Pharmaceutical Preparations

Evommune, Inc.

Quality

6.0

out of 10

Value Trap

—

Price

$23.23

Last close

Models

9/13

Active

FBRX

Pharmaceutical Preparations

Forte Biosciences, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$19.07

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	EVMN Fair Value	EVMN Upside	FBRX Fair Value	FBRX Upside
Bayesian DCF	Intrinsic	$3.72	-84.0%	$6.88	-63.9%
Earnings Power Value	Intrinsic	—	—	$6.28	-77.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.55	-89.6%	$3.94	-79.3%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EVMN vs FBRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EVMN vs FBRX — Which Stock Is More Undervalued?

EVMN scores higher with a 6.0/10 quality rating vs FBRX's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Evommune, Inc. (EVMN) and Forte Biosciences, Inc. (FBRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EVMN currently trades at $23.23 with a QOC of 6.0/10, while FBRX trades at $19.07 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).